Bluesky Facebook Reddit Email

Glyceraldehyde derivatives inspired by empagliflozin as potential anti-heart failure agents independent of glucose-lowering effects

05.08.24 | Compuscript Ltd

Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C)

Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C) keeps Macs, tablets, and meters powered during extended observing runs and remote surveys.

https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2023-0051

Announcing a new publication for Acta Materia Medica journal. Sodium-glucose cotransporter 2 inhibitors are a class of glucose-lowering drugs known for robust cardiovascular protective properties. However, the side effects induced by Sodium-glucose cotransporter 2 inhibition limit application in cardiovascular medicine.

Prior research showed that thoughtful structural modifications can dissociate the anti-heart failure activity from glucose-lowering effects. Moreover, it was shown that the glyceraldehyde derivative, JX22 , developed by scaffold hopping from empagliflozin, exhibits a superior cardiomyocyte protective effect, albeit with increased cytotoxicity compared to empagliflozin.

In this study systematic structural modifications of JX22 were performed to enhance anti-heart failure efficacy and safety, while reducing glucose-lowering activity. Twenty glyceraldehyde-based derivatives were synthesized and compound 12 emerged as an optimal candidate by exhibiting an improved cytoprotective effect compared to JX22 . Compound 12 significantly inhibited the activity of NHE1 on the myocardial membrane, thereby maintaining intracellular ion homeostasis. In vivo efficacy results demonstrated that compound 12 at 10 mg/kg significantly ameliorated cardiac dysfunction, myocardial fibrosis, and exercise tolerance in isoproterenol-induced heart failure mice without a glucose-lowering effect. Furthermore, compound 12 exhibited favorable safety profiles in single-dose toxicity and hERG inhibition tests, along with promising pharmacokinetic properties in mice.

This study not only underscores the potential of compound 12 for further investigation but also highlights the effectiveness of the scaffold hopping strategy.

# # # # # #

Acta Materia Medica welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.

Submission Process

Submissions to Acta Materia Medica are made using ScholarOne, the online submission and peer review system. Registration and access are available at https://mc04.manuscriptcentral.com/ammed

Queries about the journal can be sent to editorialoffice@amm-journal.org .

Please visit https://amm-journal.org/ to learn more about the journal.

Editorial Board: https://amm-journal.org/index.php/editorial-board/

There are no author submission or article processing fees.

Follow Acta Materia Medica on Twitter https://twitter.com/AMM_journal ; Facebook ( https://www.facebook.com/AMMjournal )

eISSN 2737-7946

Xiao Li, Yue Yao and Luoyifan Zhou et al. Glyceraldehyde derivatives inspired by empagliflozin as potential anti-heart failure agents independent of glucose-lowering effects. Acta Materia Medica. 2024. Vol. 3(2):133-146. DOI: 10.15212/AMM-2024-0009

Acta Materia Medica

10.15212/AMM-2024-0009

Keywords

Article Information

Contact Information

Conor Lovett
Compuscript Ltd
c.lovett@cvia-journal.org

How to Cite This Article

APA:
Compuscript Ltd. (2024, May 8). Glyceraldehyde derivatives inspired by empagliflozin as potential anti-heart failure agents independent of glucose-lowering effects. Brightsurf News. https://www.brightsurf.com/news/1WR33GML/glyceraldehyde-derivatives-inspired-by-empagliflozin-as-potential-anti-heart-failure-agents-independent-of-glucose-lowering-effects.html
MLA:
"Glyceraldehyde derivatives inspired by empagliflozin as potential anti-heart failure agents independent of glucose-lowering effects." Brightsurf News, May. 8 2024, https://www.brightsurf.com/news/1WR33GML/glyceraldehyde-derivatives-inspired-by-empagliflozin-as-potential-anti-heart-failure-agents-independent-of-glucose-lowering-effects.html.